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Abstract
Background: Supradiaphragmatic lymph node metastases (SdLNM) are frequently identified using 18F-FDG positron
emission tomography/computed tomography (PET/CT) in advanced epithelial ovarian cancers (AEOC). This study
aimed to determine the prognostic significance of SdLNM detected by PET/CT in patients with AEOC.
Methods: Medical records of patients diagnosed with AEOC were retrospectively registered from January 2009 to
July 2015. Patients were categorized according to PET/CT stage: PET/CT stage III, PET/CT stage IV with SdLNM, and
PET/CT stage IV with other metastases. Clinicopathologic characteristics, recurrence patterns, survival outcomes
were compared according to PET/CT stage. Anatomical distribution of SdLNM and effect of thoracic debulking
surgery were estimated.
Results: A total of 295 patients were identified, including 176 patients who underwent primary debulking surgeries
(PDS). Progression-free (P = 0.671) and overall (P = 0.525) survival did not differ significantly between patients with
PET/CT IV with SdLNM and PET/CT IV with other metastases; however, patients with PET/CT IV with SdLNM had
significantly poorer progression-free (P < 0.001) and overall (P = 0.016) survival than those with PET/CT stage III.
Recurrence patterns were similar in all groups; intraperitoneal metastasis was the most common (78.8%) and
thoracic recurrence alone accounted for less than 10%. Debulking of SdLNM lesions did not improve progression-free
survival (P = 0.425) or overall survival (P = 0.465) of patients with AEOC.
Conclusions: SdLNM detected using preoperative PET/CT are a negative prognostic factor in AEOC. Resection of
suspicious SdLNM may not have effect to survival of patients with AEOC.
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Background
Complete tumor resection is important in patients with
advanced epithelial ovarian cancer (AEOC). Although
optimal debulking surgery leaving < 1 cm of residual
tumor is known to improve the overall survival of
patients with AEOC [1, 2], complete debulking surgery
leaving no macroscopic disease can maximize the sur-
vival benefit [3, 4]. Most studies describing optimal or
no gross residual disease have only evaluated intraperito-
neal disease; only a few studies have examined extraperi-
toneal disease so far.
After introducing of 18F-FDG positron emission tom-
ography/computed tomography (PET/CT) scanning for
preoperative evaluation, extraperitoneal disease has
raised further questions about management of AEOC.
PET/CT could better discriminate malignancy from be-
nign ovarian tumor, compared to other preoperative
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imaging modalities such as ultrasonography, abdomino-
pelvic computed tomography (CT) or magnetic reson-
ance image (MRI) [5]. Distant metastases including
nodal involvement could be predicted more accurately
by preoperative PET/CT than CT [6]. Nonetheless in an
era of extensive preoperative imaging modalities, man-
agement of AEOC with supradiaphragmatic lymph node
metastasis (SdLNM) following an initial PET/CT re-
mains uncertain [7].
The prognosis of pathologically confirmed SdLNM has
not been clarified for AEOC. There has been little re-
search of the prognostic impact of SdLNM in AEOC.
Fruscio et al. found that PET/CT led to an upstaging of
about one fourth of ovarian cancer patients from stage
III to IV after SdLNM detection [8]; however, they con-
cluded that the prognosis of patients with stage IV me-
tastases detected by PET/CT was similar to that of those
at stage IIIC. In another study, recurrence pattern of
stage IV ovarian cancer patients was evaluated to deter-
mine the benefit of thoracic cytoreduction [9]; however,
since thorax-only recurrence was very rare, the authors
assumed that thoracic debulking would not change the
course of stage IV ovarian cancer. None of the previous
studies reported any association between surgical resec-
tion and pathology of SdLNM detected using PET/CT.
Therefore, this study aimed to determine the prognostic
significance of SdLNM detected using PET/CT in pa-
tients with AEOC.
Methods
Study population
We retrospectively reviewed the medical records of pa-
tients diagnosed with ovarian cancer after surgical man-
agement of pelvic mass or peritoneal disease, between
January 2009 and July 2015. Patients with available pre-
operative PET/CT scan images, at stage IIIB to IVB after
surgical staging, based on the 2014 International Feder-
ation of Obstetrics and Gynecology (FIGO) ovarian can-
cer staging system, were isolated. Clinico-pathologic
factors of those patients, such as age, initial serum can-
cer antigen 125 (CA-125) levels, histology of the epithe-
lial ovarian malignancy, and histologic grades were
collected and analyzed. This study was approved by the
institutional review board of Yonsei University College
of Medicine.
Regarding preoperative imaging modalities for suspi-
cious AEOC, patients had CT or MRI scans and PET/
CT. Based on preoperative imaging stage, medically in-
operable patients underwent neoadjuvant chemotherapy
(NAC) followed by interval debulking surgery (IDS). Pa-
tients who were scored over 8 based on the laparoscopic
prediction model [10] also underwent NAC followed by
IDS. Remaining patients underwent primary debulking
surgery (PDS). The patients in the PDS group were
further classified based on their PET/CT imaging stages.
The PET/CT stage III group included patients who had
only intraperitoneal disease without other organ involve-
ment (PET/CT III). The PET/CT stage IV group was di-
vided into two sub-groups: one group included patients
who had 18F-FDG uptake only in supradiaphragmatic
lymph nodes (SdLN), without evidence of lesions outside
the abdomen or of other organ involvement (PET/CT
IV SdLNM), and the other group included patients with
distant organ involvement, such as the liver, spleen, and
lung parenchyma, regardless of SdLN involvement
(PET/CT IV other).
The extent of surgical resection was based on the clini-
cian’s discretion, per the universal goal for AEOC to
achieve complete resection of the disease. Debulking sur-
geries including not only intra-peritoneal procedures, but
also supradiaphragmatic procedures were investigated.
Intra-peritoneal procedures included hysterectomy, bilat-
eral salpingo-oophorectomy, omentectomy, pelvic and/or
para-aortic lymphadenectomies, peritonectomy for peri-
toneal lesions, various lower gastro-intestinal system
surgeries, liver resection, and splenectomy for suspicious
lesions. Supradiaphragmatic procedures consisted of
video-assisted thoracoscopic surgery (VATS) for medias-
tinal lesions, either biopsy or excision of the supraclavicu-
lar fossa lymph node (SCFLN), and either biopsy or
excision of the axillary lymph nodes (AxLN). The resid-
uals of disease in intraperitoneal cavity after all the proce-
dures were investigated. Taxane-platinum combination
chemotherapy was done for all patients in this study,
which made more homogenous population for analysis.
Median cycle number of the chemotherapy after PDS was
6 cycles in this study. Finally, recurrences and patient sur-
vival rates were collected.
PET/CT technique
Patients were instructed to fast for over 8 h before PET
image acquisition. Blood glucose concentrations were
confirmed to be lower than 140 mg/dL; 5.5 MBq of
18F-FDG per kg body weight was injected intravenously,
with patients lying comfortably for an uptake period of
60 min. Integrated FDG-PET/CT was performed using a
dedicated PET/CT scanner (Discovery STE; GE Health-
care, Milwaukee, WI). Unenhanced CT scan was per-
formed from the vertex of the skull to the mid-thigh
using the following parameters: 120 kVp, 30 mA, 0.8-s
rotation time, 3.75mm helical thickness, 27mm per rota-
tion (speed), 2.5 mm scan reconstruction, with a recon-
struction index of 1.25mm, 15.7 cm field of view, and a
512 × 512 matrix. A PET scan was then acquired from the
cerebellum to the proximal thigh with an acquisition time
of 3min per bed position in the three-dimensional mode.
PET data were reconstructed iteratively using an ordered-
subset expectation maximization algorithm.
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Image analysis
All 18F-FDG PET/CT images were independently
reviewed visually by two nuclear medicine physi-
cians. One nuclear medicine physician has 15 years
of expertise and the other has 7 years of it. Each re-
gion with 18F-FDG uptake higher than the back-
ground was considered significant after exclusion of
physiologic uptake. For the quantitative analysis, the
maximum standardized uptake (SUVmax) values
were measured by drawing a circular region of inter-
est (ROI) at the site of the maximum 18F-FDG up-
take on transaxial PET images. The SUVmax of the
ROI was calculated as follows: [decay-corrected ac-
tivity (MBq) per tissue volume (mL)]/ [injected
18F-FDG dose (MBq) per body mass (g)]. The sizes
of the SdLNs were measured on CT images and re-
corded for data analysis.
The SdLNs consisted of five subdivisions. The lymph
nodes in the anterior mediastinal space were divided
into two groups: cardiophrenic lymph nodes (CPLN) in
the lower space and parasternal lymph nodes in the
upper space (Fig. 1a). Medial and posterior mediastinal
lymph nodes were counted as one group. In addition, di-
mensions of the SCFLN, and AxLN and their SUVmax
were measured.
Statistical analysis
To compare groups, a two-tailed Student t-test and
Fischer’s exact test were used. Kaplan-Meier estimates
and log-rank tests were performed to analyze survival.
Hazard ratios (HRs) for survival were estimated with a
Cox proportional hazards model. SPSS version 23.0
(IBM Corp, Armonk, NY, U.S.A.) was used to analyze
the data.
Results
From January 2009 to July 2015, 576 patients underwent
surgery for and were diagnosed with primary epithelial
ovarian cancer at our institution (Fig. 1b). Among them,
336 patients had staged IIIB to IVB primary epithelial
ovarian cancer. Patients who did not undergo initial
PET/CT evaluations were excluded. Finally, data from
295 patients were analyzed, of which 176 patients under-
went PDS and 119 patients underwent NAC followed by
IDS. Among the patients who underwent PDS, 108(55.9%)
belonged to the PET/CT III group. Forty patients (24.4%)
had only showed SdLNM on preoperative PET/CT scans,
and 28 patients (19.7%) showed evident involvement of
other organ on the PET/CT scans. No statistically
significant difference was noted in preoperative serum
CA-125 levels among the groups (p = 0.13). Similarly,
Fig. 1 a Five groups of supradiaphragmatic lymph node metastasis on PET/CT, b flow diagram
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other clinicopathologic characteristics including residual
disease after PDS (p = 0.405) were not significantly differ-
ent among the three groups (Table 1).
Among the patients with PDS, 50 (28.4%) had 18F-FDG
uptake in the SdLNs on preoperative PET/CT. The
most-frequent SdLNM detected by PET/CT was observed
in the SCFLN (42%) (Table 2). Median size of SdLNM was
7.65mm. There were 27 patients (54.0%) who underwent
resection of thoracic lesions for SdLNM identification, of
which two patients underwent only fine-needle biopsy for
suspicious SCFLN to confirm metastasis. For the
remaining 25 patients, a surgeon from Department of
Chest Surgery performed either VATS or thorough exci-
sion of lesions during their PDS. Among the 25 patients
who underwent thoracic debulking surgery, 21 patients
(77.8%) presented with pathologic SdLNM and four
patients had only inflammatory changes.
Of the entire study cohort, including the NAC and
PDS groups, 151 patients (51.2%) experienced recur-
rence. Intraperitoneal recurrence was the most-common
type of recurrence (78.8%), and < 10% of the patients
showed recurrence in thoracic space only (Table 3). The
recurrence patterns were similar among the three
groups, regardless of imaging stage. Three of the pa-
tients who experienced recurrence only in thoracic space
died (overall survival rate 72.7%); on the other hand, 43
patients who experienced recurrence only in the intra-
peritoneal space died (overall survival rate 63.2%). How-
ever, the survival outcomes did not show a statistical
significance (p = 0.634).
Both progression-free (P = 0.671) and overall (P =
0.525) survival did not differ significantly between pa-
tients with PET/CT IV with SdLNM and those with
PET/CT IV with other metastases; however, those with
PET/CT IV with SdLNM had significantly poorer
progression-free (median PFS: 14 months, P < 0.001) and
overall (median OS: 31.5 months P = 0.016) survival than
those with PET/CT stage III (median PFS: 18 months,
median OS: 37.5 months) (Fig. 2). Patients who had
thoracic debulking surgery during PDS did not show
a progression-free-survival (P = 0.425) or overall sur-
vival (P = 0.465) benefit compared to patients who did
not undergo a supradiaphragmatic debulking proced-
ure (Fig. 3).
There were 8 patients who had only CPLN metastases
without other extraperitoneal metastases in PET/CT,
and 42 patients had SdLNM. Although the group of the
patients with CPLN metastases only experienced lower
rate of recurrence and death, PFS and OS of the group
did not show statistical differences (p = 0.225, 0.566, re-
spectively) (Fig. 4) compared to the group of the patients
having SdLNM.
Table 1 Patient characteristics
total n % PET_CT stage III (n, %) PET_CT stage IV by
SdLNM (n, %)
PET_CT stage IV by
other (n, %)
p-value
median Age (years, IQR) 176 100 108 55.9 40 22.4 28 19.7 0.627
55 (48–63) 54 (47–63) 55 (49–63) 55 (48–60)
median initial CA-125 (U/mL, IQR) 848.05 (334.97–2387.32) 659.35 (296.20–2446.90) 1111.80 (712.0–2483.15) 1048.15 (148.45–2111.65) 0.130
FIGO stage
IIIB 11 6.3 8 7.4 3 7.5 0 0.0
IIIC 100 56.8 76 70.4 13 32.5 11 39.3
IVA 4 2.3 3 2.8 1 2.5 0 0.0
IVB 61 34.7 21 19.4 23 57.5 17 60.7 0.502
Histology
high grade serous 136 77.3 82 75.9 34 85.0 20 71.4
others 40 22.7 26 24.1 6 15.0 8 28.6 0.423
Grade
1 14 8.0 10 9.3 2 5.0 2 7.1
2 59 33.5 38 35.2 13 32.5 8 28.6
3 88 50.0 50 46.3 23 57.5 15 53.6 0.122
unknown 15 8.5 0.0 0.0 0.0
Residual disease (NGR vs other)
NGR 38 25.9 23 26.1 10 27.8 5 21.7
any residuals 109 74.1 65 72.2 26 72.2 18 78.3 0.804
unknown 29 20 4 5
NGR No gross residual disease
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No residual disease after PDS (HR = 0.52, 95% CI =
0.29–0.93, p = 0.004) and initial PET/CT stage IV includ-
ing both SdLNM and other metastases (HR = 1.61, 95%
CI = 1.13–2.29, p = 0.008) were the main contributing
factors for progression-free survival of the patients after
multivariate analysis (Additional file 1: Table S1).
Discussion
The present study showed that SdLNM detected by pre-
operative PET/CT is a significant negative prognostic
factor in AEOC. Patients in the PET/CT IV group with
SdLNM and the PET/CT IV group with other metasta-
ses showed similar survival outcomes. Moreover, resec-
tion of suspicious lymph nodes may not have affected
survival of patients with SdLNM detected by PET/CT.
To the best of our knowledge, this is the first study to
pathologically and surgically validate the results of PET/
CT for SdLNM detection and to determine their prog-
nostic impact in patients with AEOC.
The definition and location of the SdLN has been con-
fused when describing metastatic disease. These lymph
nodes, located beneath the sternum and immediately
above the heart, have been named differently as paracar-
diac, cardiophrenic, or supradiaphragmatic lymph nodes,
depending on the study [11–13]. The former two lymph
nodes are actually chest wall (parietal) lymph nodes,
which are not usually involved in lung or heart diseases
that consist of major thoracic organ problem [14]. The
chest wall lymph nodes are believed to be afferents of
whole abdominal cavity circulation [15].
Compared to CT alone, PET/CTs increase the prob-
ability of SdLNM discovery during preoperative imaging.
The advantage of whole-body PET/CT is that it allows a
surgeon to discover suspicious extra- and intra-periton-
eal metastases. Farmakis et al. found that PET/CT was
more accurate than CT alone for identifying CPLNs [16].
Similarly, Fruscio et al. also concluded that PET/CT was
a better methodology than CT for detecting distant me-
tastases in AEOC [8]: PET/CT accurately upstaged 26%
of the patients from FIGO stage III to IV during pre-
operative PET/CT imaging. In addition, Hynninen et al.
reported that preoperative PET/CT detected SdLNM
in 67% of patients with advanced ovarian cancer,
which is almost double the detection rate with CT
alone [17].
Suspicious supradiaphragmatic lymph nodes on pre-
operative image have been regarded as a negative pre-
dictor of AEOC. Holloway et al. reported a relationship
between the extent of peritoneal metastasis and enlarge-
ment of the paracardiac lymph nodes [11]. Kolev et al.
investigated supradiaphragmatic lymphadenopathy de-
tected on preoperative CT in patients with primary ovar-
ian cancer and found that patient survival decreases
with SdLN enlargement [12]. Raban et al. showed similar
results for the treatment of stage IIIC ovarian cancer:
Patients showing paracardiac lymph node enlargement
on preoperative CT scans had poorer outcomes than
those without chest lesions [18].
Notably, none of the previous studies reported a cor-
relation between pathologically identified SdLNM, which
Table 2 Incidence of supradiaphragmatic lymph node metastases (SdLNM) in PDS group
SdLNM location n % median size
(mm, range)
median SUVmax
(range)
pathologic confirmed metastasis
(N of pathologic positive /N of excision or biopsy done)
Cardiophrenic 15 30.0 7.65 (3.9–13.0) 2.6 (1.4–14.1) 8/10
Parasternal 15 30.0 6.6 (4.9–15.7) 2.4 (1.2–10.7) 7/8
middle/posterior mediastinal 7 14.0 10 (3.5–17.6) 4.2 (2.3–9.4) 1/2
Axillary 10 20.0 9 (4.4–19.3) 2.6 (1.1–8.1) 3/3
Supraclavicular or Neck node 21 42.0 9.1 (3.5–24.9) 3.2 (1.2–14.7) 5/6
Table 3 Recurrence pattern depends on primary disease extent by PET_CT
Total PET_CT stage III PET_CT stage IV by SdLNM PET_CT stage IV by other
Numbers of recurrence 151 75 41 35
Recurrent rate (%) 51.2 45.5 56.9 60.3
Location of recurrence N %
Thoracic space 11 7.3 6 8.0 2 4.9 3 8.6
Intraperitoneal space 119 78.8 60 80.0 35 85.4 24 68.6
Thoracic + Intraperitoneal space 12 7.9 5 6.7 1 2.4 6 17.1
Pleural effusion only 5 3.3 2 2.7 2 4.9 1 2.9
other (brain, bone, skin) 3 2.0 1 1.3 1 2.4 1 2.9
unknown (f/u loss) 1 0.7 1 1.3 0 0.0 0 0
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was first detected by PET/CT, and its prognostic signifi-
cance. Some studies on the detection of SdLNM by pre-
operative imaging demonstrated that presence of chest
lymph node lesions correlated with a poorer prognosis
in patients with AEOC [11, 12, 18]. However, one study
showed that in cases where PET/CT indicated stage IV
disease that was otherwise image stage III by other im-
aging modalities, the survival of the both groups would
be similar [8]. In our study, we performed either node
excision or biopsy for 54% of the patients showing
SdLNM on PET/CT, which pathologically confirmed
metastases. Based on our data, patients with SdLNM
only on preoperative PET/CT had worse outcome than
those with PET/CT stage III and had a similar
progression-free-survival rate as compared to those with
PET/CT stage IV with other metastases.
Several procedures were introduced for SdLNM re-
moval in AEOC. VATS has been evaluated as a diagnostic
tool for intra-thoracic disease, and is feasible for removal
of suspicious lesions in AEOC [19, 20]. In addition, trans-
diaphragmatic CPLN dissection also was recently intro-
duced as a feasible procedure that does not require the
assistance of a thoracic surgeon [21, 22]. However, based
on our study data, progression-free-survival of the patients
who underwent the supradiaphragmatic procedure during
the PDS was not significantly different from that of
Fig. 2 Kaplan-Meier curves of progression-free survival (a) and overall survival (b) according to PET/CT stages
Fig. 3 Kaplan-Meier curves of progression-free survival (a) and overall survival (b) according to thoracic debulking
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patients who did not undergo the procedure. In this study,
we did not observe a survival benefit for SdLNM resection
because of the small numbers of patients who underwent
thoracic debulking.
The recurrence pattern in patients with PET/CT
stage IV patients could be another factors reasonable
for the small benefit of SdLNM removal. Peri et al.
reported on the recurrence of stage IV ovarian cancer
patients [9]. Similarly, in this study, the recurrence
pattern of PET/CT stage IV ovarian cancer was simi-
lar to that of PET/CT stage IIIC cancer. Recurrence
occurred most frequently in the intra-peritoneal
space, and < 10% of the cohort demonstrated thoracic
recurrence only. These data may be further evidence
to support the fact that supradiaphragmatic proce-
dures confer little benefit to patients with the PET/
CT IV with SdLNM.
Our study and other studies question the importance
of SdLNM location in AEOC. Previous studies suggested
that the anterior chest wall lymph nodes are the major
site of SdLNM [8]; however, in this study, SCFLN metas-
tases were the most-prevalent SdLNM identified on
PET/CT. It is currently unclear whether SdLNs should
be categorized according to their origin of drainage.
Hynninen reported [17] that if there are two different
lymphatic pathways from the peritoneal cavity to the
thoracic cavity, the anterior chest wall lymph node me-
tastases would correlate with PET/CT stage III patients.
CPLN might be a thoracic marker of extensive periton-
eal stage III disease. Thus, SCFLNs drained from deep
pelvic lymph node chains might have a different prog-
nostic impact than CPLN. A redefinition of SdLNM
based on location and lymphatic afferents may impact
our understanding of residual disease after debulking
surgery in AEOC.
Despite our important findings, this study had a
limitation. Owing to its retrospective design, there may
have been a selection. However, we attempt to recruit a
homogenous patient cohort in order to analyze
progression-free survival data of patients who underwent
PDS. The strength of our study is that SdLNM detected
by PET/CT was pathologically confirmed. However, the
extent of thoracic debulking varied in this study, which
could have affected the progression-free-survival of pa-
tients who underwent the supradiaphragmatic procedure.
Conclusions
Patients with AEOC in whom SdLNM was detected
using preoperative PET/CT had a poorer prognosis than
those without SdLNM and those with other distant me-
tastases. Removal of SdLN lesions may not affect the
survival of patients with AEOC. However, further inves-
tigation is warranted to determine whether there are
location-dependent survival effects of SdLNM in pa-
tients with AEOC.
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